(-0.72%) 5 079.20 points
(-0.82%) 38 073 points
(-0.93%) 15 834 points
(-1.08%) $81.74
(-3.35%) $1.962
(-2.24%) $2 304.80
(-3.60%) $26.67
(-1.47%) $947.40
(0.41%) $0.936
(0.84%) $11.08
(0.40%) $0.799
(0.13%) $93.42
Live Chart Being Loaded With Signals
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...
Stats | |
---|---|
本日の出来高 | 7.05M |
平均出来高 | 501 174 |
時価総額 | 13.41B |
EPS | HKD0.0135 ( 2023-09-30 ) |
Last Dividend | HKD0.112 ( 2023-05-24 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -5.69 |
ATR14 | HKD0.00800 (0.24%) |
ボリューム 相関
Shenzhen Hepalink 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Shenzhen Hepalink 相関 - 通貨/商品
Shenzhen Hepalink 財務諸表
Annual | 2023 |
収益: | HKD5.45B |
総利益: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2023 |
収益: | HKD5.45B |
総利益: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2022 |
収益: | HKD7.16B |
総利益: | HKD2.33B (32.61 %) |
EPS: | HKD0.500 |
FY | 2021 |
収益: | HKD6.37B |
総利益: | HKD2.03B (31.94 %) |
EPS: | HKD0.180 |
Financial Reports:
No articles found.
Shenzhen Hepalink Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.112 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.180 | 2021-05-28 |
Last Dividend | HKD0.112 | 2023-05-24 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.333 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.36 | -- |
Div. Sustainability Score | 3.30 | |
Div.Growth Potential Score | 2.21 | |
Div. Directional Score | 2.75 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9983.HK | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
2192.HK | Ex Dividend Junior | 2023-11-07 | Annually | 0 | 0.00% | |
1198.HK | No Dividend Player | 2023-07-21 | Sporadic | 0 | 0.00% | |
0270.HK | Ex Dividend Knight | 2023-10-06 | Semi-Annually | 0 | 0.00% | |
3908.HK | Ex Dividend Junior | 2023-07-04 | Sporadic | 0 | 0.00% | |
1772.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
0811.HK | Ex Dividend Knight | 2023-05-22 | Annually | 0 | 0.00% | |
2356.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1330.HK | Ex Dividend Junior | 2023-06-28 | Annually | 0 | 0.00% | |
0386.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.144 | 1.500 | -2.88 | -4.32 | [0 - 0.5] |
returnOnAssetsTTM | -0.0408 | 1.200 | -1.360 | -1.631 | [0 - 0.3] |
returnOnEquityTTM | -0.0638 | 1.500 | -1.820 | -2.73 | [0.1 - 1] |
payoutRatioTTM | -0.544 | -1.000 | -5.44 | 5.44 | [0 - 1] |
currentRatioTTM | 2.13 | 0.800 | 4.37 | 3.49 | [1 - 3] |
quickRatioTTM | 0.756 | 0.800 | -0.256 | -0.205 | [0.8 - 2.5] |
cashRatioTTM | 0.371 | 1.500 | 9.05 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.290 | -1.500 | 5.17 | -7.76 | [0 - 0.6] |
interestCoverageTTM | -3.86 | 1.000 | -2.54 | -2.54 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.467 | -1.500 | 8.13 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.331 | 1.000 | 7.82 | 7.82 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.158 | 1.000 | -5.16 | -5.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.122 | 1.000 | -0.433 | -0.433 | [0.2 - 2] |
assetTurnoverTTM | 0.284 | 0.800 | -1.443 | -1.154 | [0.5 - 2] |
Total Score | 3.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.02 | 1.000 | -0.709 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0638 | 2.50 | -1.170 | -2.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.49 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.544 | 1.500 | -5.44 | 5.44 | [0 - 1] |
pegRatioTTM | -0.0488 | 1.500 | -3.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.125 | 1.000 | 9.38 | 0 | [0.1 - 0.5] |
Total Score | 2.21 |
Shenzhen Hepalink
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。